A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: An interferon sparing effect of t-UDCA

Hepatology Research

Volumn 23, Issue 4, 2002, Pages 227-236

  Pigozzi, Marie Gracielle ^a   Sorbara, Roberta ^a   Baisini, Ornella ^a   Di Stefano, Luciana ^a   Reggiani, Alessandro ^a   Quattrocchi, Daniela ^a   Lorini, Gianpaolo ^a   De Tavonatti, Maria Grazia ^a   Bettini, Lamberto ^a   Cominotti, Anna ^a   Favret, Maurizio ^a   Lanzini, Alberto ^a  

^a CREMONA HOSPITAL   (Italy)

Author keywords

Hepatitis C virus; Therapy of chronic hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HUMOFERON; TAUROURSODEOXYCHOLIC ACID; TUDCABIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA;

EID: 23644431868     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00007-4     Document Type: Article

References (48)

1. di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000;31:1014-8.
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
3. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9.
4. di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomised, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-62.
6. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
8. Pol S, Nalpas B, Bourliere M, Couzigou P, Tran A, Abergel A, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000;31:1338-44.
9. Liang TJ. Combination therapy for hepatitis C infection. N Engl J Med 1998;339:1549-50 editorial; comment.
10. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.
11. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Inter Med 1997;127:875-81.
12. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-5.
13. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol 1992;98:397-401.
14. Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994;19:1342-6.
15. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
17. Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 1982;23:70-80.
18. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991;14:920-6.
19. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990;12:486-91.
20. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-9.
21. Benz C, Angermuller S, Tox U, Kloters-Plachky P, Riedel HD, Sauer P, et al. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998;28:99-106.
22. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-54.
23. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
24. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
25. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98:1044-50.
26. Crosignani A, Battezzati PM, Setchell KD, Camisasca M, Bertolini E, Roda A, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991;13:339-44.
27. Simko V, Michael S, Prego V. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol 1994;89:392-8.
28. Mohler M, Seipp S, Tox U, Stremmel W, Theilmann L, Goeser T. Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C. Dig Dis Sci 1996;41:1276-7 letter.
29. Clerici C, Distrutti E, Gentili G, Solinas A, Miglietti M, Balo S, et al. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Minerva Med 1997;88:219-25.
30. Kiso S, Kawata S, Tamura S, Imai Y, Inui Y, Nagase T, et al. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial. J Gastroenterol 1997;32:56-62.
31. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-7.
32. Tanaka K, Kondo M, Sakaguchi T, Saito S, Arata S, Ikeda M, et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. J Gastroenterol Hepatol 1996;11:1155-60.
33. Fabbri C, Marchetto S, Pezzoli A, Accogli E, Fusaroli P, Azzaroli F, et al. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Eur J Gastroenterol Hepatol 2000;12:511-5.
34. Abdelmalek MF, Harrison ME, Gross JB Jr., Poterucha JJ, Gossard AA, Spivey JR, et al. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J Clin Gastroenterol 1998;26:130-4.
35. Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-9.
36. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
37. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
38. Armitage P. Statistical methods in medical research. Blackwell Scientific Publications, 1971.
39. Boucher E, Guyader D, Jacquelinet S, Andre P, Mendler MH, Turlin B, et al. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Dig Liver Dis 2000;32:29-33.
40. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomised, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
41. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
42. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
43. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
44. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr., et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993;104:595-603.
45. Podevin P, Calmus Y, Bonnefis MT, Veyrunes C, Chereau C, Poupon R. Effect of cholestasis and bile acids on interferon-induced 2′,5′-adenylate synthetase and NK cell activities. Gastroenterology 1995;108:1192-8.
46. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-7.
47. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
48. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-8.